SPC400
ropeginterferon alfa-2b
Status:
VeittApplication date:
26.8.2022Application published:
15.9.2022Grant published:
15.3.2024
Max expiry date:
14.8.2033Medicine name:
BesremiMedicine for children:
No
Timeline
Today
26.8.2022Application
15.9.2022Publication
15.3.2024Registration
14.8.2033Expires
Marketing license
IS authorization number:
EU/1/18/1352/001; EU/1/18/1352/002Date:
19.2.2019
Foreign authorization number:
EU/1/18/1352Date:
15.2.2019
Owner
Name:
PharmaEssentia Corp.Address:
13F, No. 3. Park St., Nangang District,, Taipei 115 TW
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105 Reykjavík
Patent
Number:
EP2205281